Website & contact details
- Website
Cytospire Therapeutics Limited
- Incorporated
- 24 February 2023 (3 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Casper BreumSamit HirawatAlexis Vandier
- Owned by
- Accounts type
- Small
- Region
- North West
- Address
- 3rd Floor1 Ashley RoadAltrinchamWA14 2DT
Filing status
- Accounts due
- 31 December 2027
- Last accounts
- 31 March 2026
- Conf. stmt due
- 9 March 2027
- Last conf. stmt
- 23 February 2026
Charges
- Total
- 2
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 1
Officers 9 active
Officer details are public data from the Companies House register.
Breum, Casper
Director · Appointed 12 June 2026
Danish
Born April 1967 (59)
Hirawat, Samit, Dr
Director · Appointed 15 May 2026
American
Born September 1968 (58)
Vandier, Alexis
Director · Appointed 13 May 2026
French
Born March 1974 (52)
Director · Appointed 25 March 2026
British
Born March 1986 (40)
Director · Appointed 22 November 2023
British
Born July 1986 (40)
Director · Appointed 2 May 2023
British
Born September 1979 (47)
Corporate Secretary · Appointed 24 February 2023
Goodfellow, Peter Neville
Director · Appointed 24 February 2023
British
Born August 1951 (75)
Mount, Natalie Marianne
Director · Appointed 24 February 2023
British
Born July 1972 (54)
Officer history (1 former)
12 June 2026
Appointed Breum, Casper as Director
12 June 2026
Resigned Gran, Anna Emilia, Dr as Director
15 May 2026
Appointed Hirawat, Samit, Dr as Director
13 May 2026
Appointed Vandier, Alexis as Director
25 March 2026
25 March 2026
Appointed Gran, Anna Emilia, Dr as Director
22 November 2023
2 May 2023
24 February 2023
24 February 2023
Appointed Goodfellow, Peter Neville as Director
24 February 2023
Appointed Mount, Natalie Marianne as Director
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 28 April 2023
Owns 25–50% of shares
Holds 25–50% of voting rights
Corporate
Reg. no. Sl034057
Former controllers (3)
3 October 2024
Ceased 4Bio Ventures Iii GP LLP — Owns 25–50% of shares
30 November 2023
Ceased Natalie Marianne Mount — Owns 25–50% of shares
30 November 2023
Ceased Mark Uden — Owns 25–50% of shares
Group structure 11 shown
Ownership group derived from the Companies House PSC register
Abingworth CCD 2 General Partner LLP Holds 25–50% of voting rights
Abingworth Clinical Co-Development Fund 2 GP LP Right to appoint and remove a person
Abingworth General Partner 8 LLP Holds 25–50% of voting rights
Abingworth Bioventures 8 GP LP Right to appoint and remove a person
Cytospire Therapeutics Limited This company Owns 25–50% of shares
Abingworth General Partner VI LLP Holds 75–100% of voting rights
Abingworth Bioventures VI GP LP Right to appoint and remove a person
Abingworth Avillion Blocker Limited Owns 75–100% of shares
Abingworth General Partner Vii LLP Holds 25–50% of voting rights
Abingworth Bioventures Vii GP LP Right to appoint and remove a person
What Cytospire Therapeutics say about themselves
“Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.”
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 10 November 2026 | Statement of capital following an allotment of shares | |||
| 6 August 2026 | Accounts for a small company | 31 March 2026 | ||
| 16 July 2025 | Accounts for a small company | 31 March 2025 | 11 | |
| 5 March 2025 | Confirmation statement with updates | 23 February 2025 | 4 | |
| 21 October 2024 | Cessation of a person with significant control | 1 |
Other companies at this postcode
Over 1,000 have been registered at this postcode.
Other companies in this industry
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →